Skip to content

Study · Non-randomized trial · 2011

5 results

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA12 Oct 2010Cited by 53 (Europe PMC)

PMID20938767 (opens in a new tab)PMCIDPMC3092934 (opens in a new tab)DOI10.1007/s00198-010-1379-y (opens in a new tab)PepBankPUB-20938767
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, formation markers increased significantly after one month of teriparatide regardless of prior osteoporosis therapy.

    In plain wordsIn women with osteoporosis, bone formation markers increased after one month of teriparatide, regardless of prior therapy.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation markers at one month
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · up to 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant increases in formation markers occurred after 1 month of teriparatide regardless of prior osteoporosis therapy.
    3 context sentences
    Summary · context
    We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.
    Summary · context
    We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination.
    Summary · context
    Teriparatide (20 μg/day) was administered for up to 24 months.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In women receiving teriparatide, the absolute formation marker increase at one month was lower after prior osteoporosis treatment than without prior treatment.

    In plain wordsIn women receiving teriparatide, formation markers rose less at one month after prior osteoporosis treatment than without prior treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFormation marker increase by prior therapy
    Study

    n: not reported in source

    Comparator
    Treatment-naïve patients
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The absolute increase at 1 month was lower in previously treated versus treatment-naïve patients, but after 6 months all groups reached similar levels.
    3 context sentences
    Summary · context
    We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination.
    Summary · context
    Teriparatide (20 μg/day) was administered for up to 24 months.
    Summary · context
    We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In women receiving teriparatide, prior-treatment groups reached similar formation marker levels after six months.

    In plain wordsIn women receiving teriparatide, formation marker levels were similar across prior-treatment groups at six months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFormation marker levels at six months
    Study

    n: not reported in source

    Comparator
    Other prior-treatment groups
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The absolute increase at 1 month was lower in previously treated versus treatment-naïve patients, but after 6 months all groups reached similar levels.
    3 context sentences
    Summary · context
    We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination.
    Summary · context
    Teriparatide (20 μg/day) was administered for up to 24 months.
    Summary · context
    We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women receiving teriparatide, PINP had the best signal-to-noise ratio among measured formation markers.

    In plain wordsIn women receiving teriparatide, PINP had the clearest signal relative to noise among measured formation markers.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePINP signal-to-noise ratio
    Study

    n: not reported in source

    Comparator
    Other measured formation markers
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    PINP showed the best signal-to-noise ratio.
    3 context sentences
    Summary · context
    We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.
    Summary · context
    We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination.
    Summary · context
    Teriparatide (20 μg/day) was administered for up to 24 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women receiving teriparatide, baseline PINP correlated positively and significantly with BMD response at 24 months.

    In plain wordsIn women receiving teriparatide, higher baseline PINP was linked to greater bone density response at 24 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBaseline PINP association with BMD response
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Baseline PINP correlated positively and significantly with BMD response at 24 months.
    3 context sentences
    Summary · context
    We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination.
    Summary · context
    Teriparatide (20 μg/day) was administered for up to 24 months.
    Summary · context
    We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.